INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease with an approximate prevalence of 20-30% in the Western countries and 16-33% in Korea \[[@b1-cmh-22-1-146]\]. As the pathogenesis of NAFLD is closely related to insulin resistance \[[@b2-cmh-22-1-146],[@b3-cmh-22-1-146]\], the development of NAFLD has been related to various components of metabolic syndrome such as, dyslipidemia, obesity, type II diabetes and cardiovascular disease \[[@b4-cmh-22-1-146]\]. Therefore, NAFLD has been considered to be a hepatic manifestation of metabolic syndrome \[[@b5-cmh-22-1-146]\].

Vitamin D is a fat-soluble vitamin, that affects metabolism including immune function and bone metabolism \[[@b6-cmh-22-1-146]\]. It is formed in the skin or obtained from the diet. In the liver, vitamin D can be metabolized to 25-hydroxyvitamin \[25(OH)D\], which is its major circulating metabolite. Many studies have linked low levels of vitamin with metabolic syndrome, type II diabetes mellitus (DM), metabolic bone diseases and obesity \[[@b7-cmh-22-1-146]-[@b9-cmh-22-1-146]\]. A recent meta-analysis of both Western and Eastern cohort studies showed that NAFLD patients have decreased serum 25(OH)D concentrations \[[@b10-cmh-22-1-146]\]. However, few studies of vitamin D levels and NAFLD in populations in Korea have been previously reported. In Korea, a cross-sectional study showed that lower 25(OH)D~3~ levels were associated with a significantly increased risk of NAFLD, independent of obesity and metabolic syndrome \[[@b11-cmh-22-1-146]\]. However, in the previous study, the cohort included only males. Therefore, we aimed herein to investigate the association between NAFLD and serum vitamin D levels in the apparently healthy individuals in Korea.

PATIENTS AND METHODS
====================

Study population
----------------

A cross-sectional study was performed to investigate the association between the serum concentrations of vitamin D and NAFLD. Participants who examined serum vitamin D tests and abdominal ultrasonography at the Seoul National University Hospital Gangnam Healthcare Center in Seoul, Republic of Korea for routine health check-ups from January 2010 to September 2010 were recruited. Most of the subjects spontaneously paid for their health check-ups, while some of the participants were supported by their employer.

We excluded subjects with other potential causes of chronic liver disease, including 291 subjects positive for hepatitis B virus, 134 for positive for hepatitis C virus, and 598 with a history of significant alcohol consumption (\>30 g/day for males and \>20 g/day for females) or a history of hepatitis from other causes. Ultimately, 5,409 subjects were enrolled. This study was approved by the Institutional Review Board of the Seoul National University Hospital with a waiver of informed consent.

Clinical and laboratory assessments
-----------------------------------

Each subject completed a questionnaire regarding their past medical history and lifestyle. All subjects participated in anthropometric assessment and the laboratory and radiologic tests on the same day. Height and body weight were measured using a digital scale, and body mass index (BMI) was calculated by dividing the weight (kg) by the square of the height (m2 ). Waist circumference was measured at the midpoint between the lower costal margin and the anterior superior iliac crest by a well-trained examiner using a tape. Blood pressures were measured twice, and the mean values were reported. Hypertension was defined as either a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg or current use of anti-hypertensive medication. Serum samples were collected after 12 hours overnight fast. DM was defined as a fasting glucose level ≥126 mg/dL or current use of anti-diabetic medication. Laboratory tests included serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), fasting glucose, triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hepatitis B surface antigen and antibody to hepatitis C virus.

Serum vitamin D levels
----------------------

Serum levels of 25-hydroxyvitamin(OH)D~3~ were measured using a chemiluminescnece immunoassay kit (Diasorin, Stillwater OK, OK ,USA). Subjects were categorized as having either low vitamin D levels (\<20 ng/mL), or normal vitamin D levels (≥20 ng/mL) \[[@b12-cmh-22-1-146]\]. Additionally, quintile 1 of serum vitamin D level was ≤14.4 ng/mL, quintile 2 was 14.5-18.8 ng/mL, quintile 3 was 18.9-23.1 ng/mL, quintile 4 was 23.2-28.8 ng/mL, and quintile 5 was ≥28.9 ng/mL. We used the lowest quintile (≤14.4 ng/mL) of vitamin D levels as a reference group.

Assessment of NAFLD
-------------------

NAFLD was defined as the presence of fatty liver as determined via ultrasonography in the absence of the following: 1) hepatitis B surface antigen seropositivity or antibody to hepatitis C virus, 2) significantly excessive alcohol consumption (\>30 g/day for males or \>20 g/day for females), 3) medications previously known to induce fatty liver disease, and 4) other known causes of hepatic disease. Ultrasonographic examinations of the liver were performed by experienced radiologists who were blinded to the clinical information using a 3.5-MHz transducer (Acusion, Sequoia 512, Siemens, Mountain View, CA, USA). Diagnoses of fatty liver were based on the following previously established standardized definitions \[[@b13-cmh-22-1-146]\]: hepatorenal echo contrast, liver brightness, deep attenuation and vascular blurring.

Statistical analysis
--------------------

Categorical variables were compared using a chi-square test or Fisher's exact test and continuous variables between the two groups were performed using the Student's t-test. Logistic regression analysis was used to analyze the associations between NAFLD and serum levels of 25(OH)D~3~. Multivariate logistic regression analysis was performed to identify independent risk factors after adjusting other confounders. Statistical analyses were performed using SPSS 19.0 (SPSS Inc.; Chicago, IL, USA). *p*-value \<0.05 was considered statistically significant.

RESULTS
=======

Study population
----------------

A total of 5,409 subjects (mean age 51.7±10.3, female 54.7%) were analyzed. Of the 5,409 subjects, 1,660 (30.7%) subjects had ultrasonographically diagnosed NAFLD. [Table 1](#t1-cmh-22-1-146){ref-type="table"} compares the subjects with and without NAFLD. Individuals with NAFLD showed an older age, a higher prevalence of DM and hypertension, higher BMIs, waist circumference, AST, ALT, GGT, triglycerides, HDL-cholesterol and fasting glucose and were also more frequently of the male gender compared with those without NAFLD. There was no significant difference in the levels of 25(OH)D~3~ between the two groups.

Relationship between 25(OH)D~3~ and NAFLD
-----------------------------------------

To analyze the relationship between NAFLD and the levels of 25(OH)D~3~, multivariable binary and ordinal analyses were performed with NAFLD as a dependent variable ([Table 2](#t2-cmh-22-1-146){ref-type="table"}). NAFLD was significantly inversely associated with vitamin D levels after adjusting for age and sex \[odds ratio (OR) 0.85, 95% confidence interval (CI) 0.75-0.96\]. The age and sex-adjusted prevalence of NAFLD decreased steadily with increasing levels of vitamin D \[OR 0.74, 95% CI=0.60-0.90, lowest quintile (≤14.4 ng/mL) vs highest quintile (≥28.9 ng/mL), *p* for trend \<0.001\]. Multivariate regression analysis after adjusting for BMI, waist circumference, triglycerides, HDL cholesterol, LDL cholesterol, diabetes, and hypertension revealed that NAFLD was statistically significantly inversely associated with vitamin D levels (\>20 ng/mL) \[OR 0.87, 95% CI, 0.75-0.99\] and the grade of vitamin D levels in a dose-dependent manner \[OR=0.93, 95% CI 0.74-1.16 in 3rd quintile (18.9-23.1 ng/mL), OR 0.89, 95% CI 0.71-1.11 in the 4th quintile (23.2-28.8 ng/mL) and OR 0.73, 95% CI, 0.58-0.91 in 5th quintile vs the lowest quintile, *p* for trend=0.002\].

DISCUSSION
==========

In the present study, we found that serum concentrations of vitamin D, even within the normal range, were inversely associated with NAFLD in a dose-dependent manner. This association was independent of various well-identified metabolic risk factors for NAFLD, including age, sex, BMI, waist circumference, DM, hypertension, and levels of LDL- and HDL-cholesterol. These findings suggest an important role for vitamin D in the pathogenesis of NAFLD.

In accord with our findings, many previous studies have suggested inverse relationships between vitamin D and NAFLD. A systematic review showed that NAFLD patients were 1.26-times more likely to be vitamin D deficient. Interestingly, these differences were higher in Western populations than in Eastern populations \[[@b10-cmh-22-1-146]\]. Targher et al. \[[@b14-cmh-22-1-146]\] reported that patients with biopsy-confirmed NAFLD showed a marked reduction in serum 25(OH) D~3~ levels compared with controls. In another study of 262 subjects performed in Italy, low 25(OH) D~3~ levels were associated with NAFLD independent of insulin-resistance, diabetes and metabolic syndrome \[[@b15-cmh-22-1-146]\]. In contrast, a Chinese population based-survey showed that vitamin D status was not significantly associated with NAFLD \[[@b16-cmh-22-1-146]\].

However, few studies have assessed the association between vitamin D levels and NAFLD in Korea. In a recent study of healthy Korean men, the proportion of NAFLD patients increased as the serum 25(OH)D~3~ levels decreased and multiple logistic regression analyses showed that the lower 25(OH)D~3~ tertile levels were associated with a significantly increased risk of NAFLD compared with the highest tertile after adjusting for metabolic syndrome \[[@b10-cmh-22-1-146]\]. However, that study included only men, which introduced a selection bias. Another study performed with a population-based cohort in Korea reported that low vitamin D status was closely associated with NAFLD, independent of visceral fat, as measured by computed tomography \[[@b17-cmh-22-1-146]\]. The results of the present study, which had a relatively large-scale cohort that included both men and women confirmed these findings. In our study, although the highest quintile of vitamin D showed significantly inverse relationship with the presence of NAFLD, there was no significant risk increase of NAFLD according to low vitamin D levels from 2nd to 4th quintiles. These results suggest the protective effect of vitamin D on NAFLD is more profound when serum levels of vitamin D level are more sufficient.

The underlying mechanism for the role of vitamin D in the development of NAFLD has not been clearly elucidated. In a previous animal study, rats fed with vitamin D depletion, the vitamin-deficient group showed greater hepatic steatosis and inflammation through toll-like receptor activation compared with the control group \[[@b18-cmh-22-1-146]\].

Median vitamin D concentrations varied among previous studies. However, the reasons for these differences are unclear. Ultraviolet B exposure, dietary vitamin D consumption, vitamin D fortification habits in various countries and differences in the season of samplings may have resulted in the different findings \[[@b19-cmh-22-1-146]\]. Moreover, the 25(OH)D assays were not standardized because of the use of different assay materials \[[@b20-cmh-22-1-146],[@b21-cmh-22-1-146]\]. To date, there is no consensus on ideal cut-off levels for vitamin D deficiency, and various factors such as geography, sex and season may need to be considered.

There were several drawbacks in this study. First, its cross-sectional design made it difficult to confirm temporal associations between vitamin D levels and NAFLD. Second, we could not obtain results of liver histology, which is the gold standard for NAFLD diagnosis. Although, ultrasonography might introduce false-negative outcomes when fatty infiltration of the liver falls below 30% \[[@b22-cmh-22-1-146]\], it is not possible to perform invasive tests in evidently healthy population. Therefore, ultrasonography was used as a first-line method to diagnose NAFLD according to current clinical guidelines \[[@b23-cmh-22-1-146],[@b24-cmh-22-1-146]\]. Third, we could not exclude subjects who were taking vitamin D supplements and we did not consider seasonal variations of vitamin D levels in our analysis. Finally, we could not obtain data of physical activity such as exercise or outdoor activity, which could be a confounding factor for both NAFLD and serum vitamin D levels.

In conclusion, our findings show that serum vitamin D, even within the normal range, was found to be inversely associated with NAFLD in a dose-dependent manner. Vitamin D levels were inversely associated with NAFLD independent of known metabolic risk factors. Thus, vitamin D may exert a protective effect against NAFLD.
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###### 

Comparison of baseline characteristics between subjects with and without nonalcoholic fatty liver disease

                                NAFLD (n=1,660)   Control (n=3,749)   *P*-value
  ----------------------------- ----------------- ------------------- -----------
  Age (years)                   53.6±9.5          50.9±10.5           \<0.001
  Male (%)                      1,069 (64.4)      1,382 (36.9)        \<0.001
  Diabetes mellitus (%)         121 (7.3)         103 (2.70)          \<0.001
  Hypertension (%)              498 (30.0)        589 (15.8)          \<0.001
  Body mass index (kg/m^2^)     25.29±2.92        22.30±2.67          \<0.001
  Waist circumference (cm)      89.63±8.03        81.10±7.99          \<0.001
  AST (IU/L)                    25.9±12.4         21.2±7.5            \<0.001
  ALT (IU/L)                    31.6±20.6         19.7±11.3           \<0.001
  GGT (IU/L)                    41.9±36.4         26.2±25.8           \<0.001
  Cholesterol (mg/dL)           198.9±36.0        193.1±33.6          \<0.001
  Triglycerides (mg/dL)         144.8±84.0        88.7±50.0           \<0.001
  HDL cholesterol (mg/dL)       48.0±10.0         55.4±12.0           \<0.001
  Fasting glucose (mg/dL)       104.8±21.8        93.4±13.5           \<0.001
  25(OH) Vitamin D~3~ (ng/mL)   21.75±7.54        22.02±8.43          0.253

Data represent means±SD.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease

###### 

Age- and sex-adjusted and multivariable binary and ordinal analyses of the risk of nonalcoholic fatty liver disease

  Vitamin D3         Age, sex adjusted   *P*-value                                              Multivariable model 1   *P*-value                                              Multivariable model 2   *P*-value
  ------------------ ------------------- ------------------------------------------------------ ----------------------- ------------------------------------------------------ ----------------------- ------------------------------------------------------
  ≤20 ng/mL          1 (reference)                                                              1 (reference)                                                                  1 (reference)           
  \>20 ng/mL         0.85 (0.75-0.96)    0.010                                                  0.86 (0.75-0.99)        0.032                                                  0.87 (0.75-0.99)        0.049
  Quintile                                                                                                                                                                                             
   1st (-14.4)       1 (reference)       0.001^[\*](#tfn1-cmh-22-1-146){ref-type="table-fn"}^   1 (reference)           0.003^[\*](#tfn1-cmh-22-1-146){ref-type="table-fn"}^   1 (reference)           0.002^[\*](#tfn1-cmh-22-1-146){ref-type="table-fn"}^
   2nd (14.5-18.8)   1.14 (0.94-1.38)                                                           1.09 (0.88-1.35)                                                               1.07 (0.85-1.34)        
   3rd (18.9-23.1)   0.96 (0.79-1.17)                                                           0.93 (0.76-1.15)                                                               0.93 (0.74-1.16)        
   4th (23.2-28.8)   0.95 (0.79-1.16)                                                           0.93 (0.75-1.15)                                                               0.89 (0.71-1.11)        
   5th (28.9-)       0.74 (0.61-0.90)                                                           0.75 (0.60-0.93)                                                               0.73 (0.58-0.91)        

Multivariable model 1 was adjusted for age, sex, body mass index, waist circumference, diabetes, and hypertension. Multivariable model 2 includes diabetes, hypertension, low‐density lipoprotein cholesterol, and high‐density lipoprotein cholesterol in addition to the variables addressed in model 1.

OR, odds ratio; CI, confidence interval.

*P*-value for test of trend of odds.
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